Cargando…

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ataei-Nakhaei, Saeideh, Aryana, Kamran, Mostafavi, Sayyed Mostafa, Kosari, Hadis Mohammadzadeh, Esmatinia, Mohammad, Aghaee, Atena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832896/ https://www.ncbi.nlm.nih.gov/pubmed/35315988 http://dx.doi.org/10.20945/2359-3997000000451

Ejemplares similares

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Radioligand Therapy with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Toxicity and Tolerability of (177)Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
por: Khatami, Alireza, et al.
Publicado: (2022)

Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
por: Jiang, Yuanyuan, et al.
Publicado: (2022)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Radiation exposure assessment of nuclear medicine staff administering [(177)Lu]Lu-DOTA-TATE with active and passive dosimetry
por: Riveira-Martin, Mercedes, et al.
Publicado: (2023)

Predictive power of the post-treatment scans after the initial or first two courses of [(177)Lu]-DOTA-TATE
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

Combination of [(177)Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
por: Simón, Marina, et al.
Publicado: (2022)

Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center
por: Silva, Maria Manuel, et al.
Publicado: (2023)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
por: Mazzara, Christophe, et al.
Publicado: (2022)

Clinical implementation of PLANET® Dose for dosimetric assessment after [(177)Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
por: Santoro, Lore, et al.
Publicado: (2021)

Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

[(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study
por: Wang, Hao, et al.
Publicado: (2018)

SUN-329 177Lu-DOTA-TATE Treatment in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors: A Single-Center 7-Year Experience
por: Gouveia, Pedro, et al.
Publicado: (2019)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

[(177)Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
por: Spada, Francesca, et al.
Publicado: (2021)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on (99m)Tc-Octreotide and posttherapeutic (177)Lu-DOTA-TATE scans
por: Amoui, Mahasti, et al.
Publicado: (2021)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ajbkllus4kco69c23q5kc7ddrg